Effect of rituximab on primary central nervous system lymphoma: a meta-analysis.

about

Effect of rituximab on primary central nervous system lymphoma: a meta-analysis.

Item

http://www.wikidata.org/entity/Q47813195

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Effect of rituximab on primary central nervous system lymphoma: a meta-analysis.

@en

Effect of rituximab on primary central nervous system lymphoma: a meta-analysis.

@nl

type

Item

label

Effect of rituximab on primary central nervous system lymphoma: a meta-analysis.

@en

Effect of rituximab on primary central nervous system lymphoma: a meta-analysis.

@nl

prefLabel

Effect of rituximab on primary central nervous system lymphoma: a meta-analysis.

@en

Effect of rituximab on primary central nervous system lymphoma: a meta-analysis.

@nl

P1476

Effect of rituximab on primary central nervous system lymphoma: a meta-analysis.

@en

P2093

Mingzhi Zhang

http://www.w3.org/2001/XMLSchema#string

Weili Xue

http://www.w3.org/2001/XMLSchema#string

Yanjie Zhang

http://www.w3.org/2001/XMLSchema#string

Yibo Wen

http://www.w3.org/2001/XMLSchema#string

Yue Song

http://www.w3.org/2001/XMLSchema#string

P2860

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

Practical methods for incorporating summary time-to-event data into meta-analysis

Novel CD20 monoclonal antibodies for lymphoma therapy

Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.

CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009.

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project

High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma.

Rituximab: mechanism of action and resistance.

Rituximab monotherapy for patients with recurrent primary CNS lymphoma.

P2888

s12185-017-2316-z

P304

612-621

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.1007/S12185-017-2316-Z

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

106

http://www.w3.org/2001/XMLSchema#string

P577

2017-09-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28900847

http://www.w3.org/2001/XMLSchema#string